MHRA approves Astellas’ Vyloy combination for gastric cancer
Most cases go undetected until an advanced stage, as the disease rarely causes early symptoms
Read More
Tag: Astellas
Seagen and Astellas announce results from EV-302 study
Trial involves the use of Padcev and Keytruda among patients with certain types of urothelial cancer
Read More
Positive results for Astellas’ Fezolinetant
Trial involved over 450 women across Europe, Turkey and Canada who were unsuitable for hormone therapy
Read More
Astellas and Pfizer reveal positive results for Xtandi
Research data follows phase 3 EMBARK trial and involves men with non-metastatic prostate cancer
Read More
Affinivax, Astellas’ pneumococcal vaccine wins breakthrough therapy status
At the same time, Affinivax and Astellas revealed positive results from the Phase II trial of ASP3772
Read More
Astellas’ Xtandi bags NICE approval in prostate cancer
Oral androgen receptor signalling inhibitor now approved to treat metastatic hormone-sensitive prostate cancer
Read More
EMA accepts Astellas/Seagen’s enfortumab vedotin for review
Marketing authorisation application is seeking approval for advanced urothelial cancer
Read More
Astellas to acquire iota Biosciences following R&D partnership
Companies will develop ultra-small implantable medical devices
Read More
NICE publishes guidance on Astellas’ Xospata
The final green light backs NHS use of the drug
Read More
NICE backing for Astella’s Xospata
The drug is considered a cost-effective treatment for relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia
Read More
Astellas, Audentes pen $3bn gene therapy deal
Genetic regulation is set to become a fifth primary focus for the Japanese drugmaker, on top of its already existing business lines.
Read More
First patient dosed in Astellas’ late-stage menopause trial
The study will evaluate the drug in menopause related vasomotor symptoms, such as hot flashes and night sweats.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
